New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Akeso, Ascentage, Astellas, Biosion, Cstone, Innovent, Inventisbio, Pharmabcine, Pyxis, Qihan, Seagen.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Akeso, Ascentage, Celsion, Foghorn, Onconano.
New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research annual meeting, including: Alpine, Apexigen, Basilea, Biopath, CG, Chemocentryx, Cstone, Deciphera, Erasca, Gritstone, Highlight, Kineta, Mustang, Neoimmunetech, Neoleukin, Oric, Portage, Sotio, Trishula.
The tumor microenvironment is critical for the ability of cancers to survive and grow, and some aspects of the microenvironment are studied, and targeted, accordingly. Tumor immunology is one of the most active areas of cancer research and has become a pillar of treatment. Others, not so much. “The nervous system is the last component of the microenvironment that people have left completely unrecognized,” Humsa Venkatesh told BioWorld. Even in brain tumors and metastases, where the presence of neurons is glaringly obvious, there has been little attention to how the two interact until recently.
RSS
